In the last decade, engineered nanoparticles have become an important class of new materials with several properties that make them very attractive for commercial development.
The preclinical studies conducted in our state-of-the-art-research laboratory, primarily focus on the assessing the efficacy of the drugs, their safety, probable mechanism of action, pharmacokinetic and pharmacodynamic properties.
